Curetis N.V announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing. To this end, Curetis has signed a Supply and Authorization Agreement as well as a further R D Collaboration and Service Agreement with MGI, a fully-owned subsidiary of BGI Group, one of the world's leading genome sequencing centers headquartered in Shenzhen, Guangdong, P. R. China. The parties aim to integrate Curetis' patented Unyvero Lysator-based sample preparation technology and MGI's NGS next generation sequencing technology to develop a fully automated workflow that allows the processing of any type of native clinical sample with the subsequent NGS-based detection of microbial pathogens and genetic markers for antibiotic resistances. Under the terms of the agreement and subject to certain conditions, MGI will reimburse Curetis for supporting the workflow integration and transferring this advanced technology, and pay technology access fees, a transfer price on OEM hardware and consumables, and royalties on product sales.